HCRN-GU21-517
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY)
Status: Open to Accrual
Learn more:
Study Contact: studies@hoosiercancer.org; (317) 921-2050.
Abstracts/Posters/Presentations:
- Y Chen, L Liu, M Pu, S Pena, Q Qin, T Zhang, H Emamekhoo, J Michael Lang, A Patnaik, RR McKay. A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY) (HCRN-GU21-517). Trials in Progress, 2024 ASCO GU. See abstract.
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter